Physician profile
William Gillespie
NPI 1538238118
$16,321.73
in general payments reported to CMS, 2019-2025
31 companies · $2,640 in 2025
The $2,640 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,287 · 2020: $1,818 · 2021: $2,260 · 2022: $1,929 · 2023: $2,473 · 2024: $2,915 · 2025: $2,640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,825 · Education: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,825.34 |
| Education | $202.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,244.08 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $1,812.01 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $1,474.23 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,432.43 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $1,333.25 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $1,206.70 | 2019-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,058.40 | 2020-2025 | Caplyta |
| Lundbeck LLC | $1,013.68 | 2019-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $780.07 | 2019-2022 | |
| Indivior INC. | $569.18 | 2019-2024 | Perseris |
| Allergan, INC. | $479.53 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $434.74 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $425.62 | 2019-2025 | Trintellix |
| Bausch Health US, LLC | $421.58 | 2019-2025 | Aplenzin |
| Idorsia Pharmaceuticals US INC | $367.79 | 2022-2025 | Quviviq, Quviviq |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $291.27 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $156.38 | 2024-2025 | Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $144.18 | 2025 | Rexulti |
| Almatica Pharma LLC | $140.96 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Supernus Pharmaceuticals, INC. | $116.38 | 2021-2023 | Qelbree |
| Tris Pharma INC | $115.32 | 2023-2025 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $70.73 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $57.06 | 2019-2020 | |
| Eisai INC. | $47.88 | 2021 | |
| Corium, LLC | $38.48 | 2024 | Azstarys |
| Tms Neurohealth Centers INC. | $21.73 | 2025 | Tms Neurohealth Centers INC. |
| Alfasigma USA, INC. | $20.15 | 2020 | |
| Ironshore Pharmaceuticals INC. | $14.42 | 2019 | |
| Luye Pharma (USA) LTD. | $13.80 | 2025 | Erzofri Extended-Release |
| Noven Therapeutics, LLC | $10.99 | 2020 | |
| Sumitomo Pharma America, INC. | $8.71 | 2023 | Latuda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Gillespie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.